Eris Lifesciences peers

·Pharma & HealthChart ›

Companies like Eris Lifescienceslatest year

Eris LifesciencesERIS · FY26 · this company
Market cap₹15,091
P/E24.04×
Sales growth+12.6%
ROE18.3%
Mankind PharmaMANKIND · FY26
Open ›
Market cap₹91,142
P/E47.64×
Sales growth+17.3%
ROE12.5%
Ajanta PharmaceuticalsAJANTPHARM · FY26
Open ›
Market cap₹41,177
P/E38.86×
Sales growth+32.5%
ROE25.4%
Torrent PharmaceuticalsTORNTPHARM · FY26
Open ›
Market cap₹1,52,307
P/E70.40×
Sales growth+50.8%
ROE27.1%

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ERIS₹1,089.60

Eris Lifesciences Ltd.

· Pharma & Health
₹ CrorePeersMANKINDAJANTPHARMTORNTPHARMEMCUREGRANULESCONCORDBIOINDGNCAPLIPOINTMcap ₹15,091 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
ERIS
FY26
MANKIND
FY26
AJANTPHARM
FY26
TORNTPHARM
FY26
Peer
Average
Valuation — at last close
P/E◆ 24.04×47.64×38.86×70.40×52.30× -54%
P/B◆ 3.87×5.59×9.10×18.16×10.95× -65%
EV/EBITDA◆ 15.47×26.45×29.20×38.23×31.29× -51%
Market Cap₹15,091 Cr₹91,142 Cr₹41,177 Cr₹1.52L Cr₹94,876 Cr -84%
Growth
Revenue CAGR 3Y◆ 22.92%17.73%13.37%13.27%14.79% +55%
Revenue CAGR 5Y◆ 20.89%—13.54%11.80%12.67% +65%
Net Income CAGR 3Y20.06%13.96%◆ 21.55%19.75%18.42% +9%
Revenue YoY (latest Q)12.61%17.33%32.53%◆ 50.79%33.55% -62%
Net Income YoY (latest Q)39.17%37.67%◆ 49.18%-9.64%25.74% +52%
Profitability
EBITDA Margin◆ 35.79%25.34%25.58%32.61%27.84% +29%
Net Income Margin◆ 20.69%13.57%19.37%15.29%16.08% +29%
Return on Common Equity18.34%12.49%25.39%◆ 27.07%21.65% -15%
Return on Capital Employed15.37%12.51%◆ 27.90%14.88%18.43% -17%
Return on Assets8.99%6.94%◆ 18.91%7.21%11.02% -18%
Credit & Quality
Total Debt/Equity0.59×0.38×◆ 0.05×0.84×0.42× +39%
Interest Coverage4.36×4.27×◆ 75.83×8.94×29.68× -85%
Scale — latest FY
Revenue / Total Income₹3,129 Cr₹14,278 Cr₹5,453 Cr₹13,980 Cr₹11,237 Cr -72%
Net Income₹648 Cr₹1,938 Cr₹1,056 Cr₹2,138 Cr₹1,711 Cr -62%
Total Assets₹7,366 Cr₹28,080 Cr₹6,155 Cr₹44,312 Cr₹26,182 Cr -72%
EPS₹45.33₹46.35₹84.53₹63.92₹64.93 -30%
Book Value per Share₹281.78₹394.87₹361.16₹247.86₹334.63 -16%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.